China authorized self-developed oral antiviral drug GST-HG171 for clinical trials for COVID-19 treatment, said the drug developer on Sunday, emphasizing the drug's effective antiviral capacity against the original variant, the Beta variant, the Delta variant, and the Omicron BA.4 and BA.5 variants.According to a statement released by Fujian Cosunter Pharmaceutical Co., Ltd, the developer of the oral antiviral drug GST-HG171, the company got approval from the Chinese National Medical Products Administration (NMPA) on September 23.GST-HG171 has been approved for clinical trials to treat mild-to-moderate COVID-19 in adults, the statement said.An inhibitor of the 3C-like protease in the coronavirus, the drug demonstrated excellent antiviral efficacy and safety in pre-clinical studies in animals, said Cosunter.More than 10 self-developed oral drugs for COVID-19 treatment are currently being researched and developed in China.On July 25, the NMPA granted conditional approval to Azvudine, the first Chinese-made oral antiviral drug to treat COVID-19, five months after giving conditional approval to Pfizer's COVID-19 treatment drug Paxlovid in February.China releases therapeutic effect of first COVID-19 oral drugNation cannot risk seniors by relaxing COVID policyChina authorized self-developed oral antiviral drug GST-HG171 for clinical trials for COVID-19 treatment, said the drug developer on Sunday, emphasizing the drug's effective antiviral capacity against the original variant, the Beta variant, the Delta variant, and the Omicron BA.4 and BA.5 variants.According to a statement released by Fujian Cosunter Pharmaceutical Co., Ltd, the developer of the oral antiviral drug GST-HG171, the company got approval from the Chinese National Medical Products Administration (NMPA) on September 23.GST-HG171 has been approved for clinical trials to treat mild-to-moderate COVID-19 in adults, the statement said.An inhibitor of the 3C-like protease in the coronavirus, the drug demonstrated excellent antiviral efficacy and safety in pre-clinical studies in animals, said Cosunter.More than 10 self-developed oral drugs for COVID-19 treatment are currently being researched and developed in China.On July 25, the NMPA granted conditional approval to Azvudine, the first Chinese-made oral antiviral drug to treat COVID-19, five months after giving conditional approval to Pfizer's COVID-19 treatment drug Paxlovid in February.China releases therapeutic effect of first COVID-19 oral drugNation cannot risk seniors by relaxing COVID policy
